Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Randomized, Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus

NCT02751996 is registered in ClinicalTrials.gov with F-star Therapeutics, Inc. as lead sponsor.

NCT NCT02751996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02751996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Randomized, Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus
Lead sponsor
F-star Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2016
Completion date
February 10, 2020
Enrollment
80 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b, hepatitis, viral